Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins

(2020) Kavita Singh et al.   Communications Biology

From high to low malaria transmission in Zanzibar—challenges and opportunities to achieve elimination

(2019) A. Björkman et al.   BMC Medicine

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230

(2019) Puthupparampil V. Scaria et al.   npj Vaccines

Trends in parasite prevalence following 13 years of malaria interventions on Bioko island, Equatorial Guinea: 2004–2016

(2018) Jackie Cook et al.   MALARIA JOURNAL

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults

(2018) Issaka Sagara et al.   LANCET INFECTIOUS DISEASES

Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A

(2018) Martin Burkhardt et al.   VACCINE

Two-Faced Immunity? The Evidence for Antibody Enhancement of Malaria Transmission

(2018) Will Stone et al.   TRENDS IN PARASITOLOGY

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate

(2017) Andrea J. Radtke et al.   Scientific Reports

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of thePlasmodium falciparumSexual Stage Protein Pfs230

(2016) Nicholas J. MacDonald et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial

(2016) M. Tashani et al.   VACCINE

Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay

(2016) Kazutoyo Miura et al.   VACCINE

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

(2016) Kawsar R. Talaat et al.   PLoS One

Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum

(2015) M. C. Kapulu et al.   Scientific Reports

Malaria Parasites Co-opt Human Factor H to Prevent Complement-Mediated Lysis in the Mosquito Midgut

(2013) Nina Simon et al.   Cell Host & Microbe

Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle

(2013) Richard L. Shimp et al.   VACCINE

Economic analysis of the global polio eradication initiative

(2010) Radboud J. Duintjer Tebbens et al.   VACCINE

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

(2008) Yimin Wu et al.   PLoS One